{
    "clinical_study": {
        "@rank": "79043", 
        "arm_group": [
            {
                "arm_group_label": "Repaglinide", 
                "arm_group_type": "Experimental", 
                "description": "Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily."
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values."
            }
        ], 
        "brief_summary": {
            "textblock": "The prevalence of diabetes is up to 11.6% according to the data released in 2013 by the\n      China Noncommunicable Disease Surveillance Group.Less than 40% of all diagnosed-diabetes\n      were well controlled.Among all kinds of antidiabetic medications, metformin is recommended\n      as the first-line antihyperglycemic management for type 2 diabetes. Insulin\n      secretagogue,repaglinide is still one of the most widely used antidiabetic medications in\n      China. However, there were few studies comparing the effects of these two medications on\n      glycaemic control in Chinese patients with type 2 diabetes."
        }, 
        "brief_title": "Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All participants with type 2 diabetes, diagnosed by World Health Organization\n             criteria, were recruited from outpatient of the Endocrinology Department in Shanghai\n             Renji Hospital\n\n        Exclusion Criteria:\n\n          -  Patients who had a history of coronary heart disease, abnormal renal function, active\n             liver disease, chronic metabolic acidosis (including diabetic ketoacidosis), or\n             severe chronic gastrointestinal disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "107", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040246", 
            "org_study_id": "NSFC-81070651"
        }, 
        "intervention": [
            {
                "arm_group_label": "Repaglinide", 
                "description": "Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.", 
                "intervention_name": "Repaglinide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metformin", 
                "description": "Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Repaglinide", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200127"
                    }, 
                    "name": "Renji Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200127"
                    }, 
                    "name": "Renji Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "HbA1c change from baseline", 
            "safety_issue": "No", 
            "time_frame": "week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040246"
        }, 
        "responsible_party": {
            "investigator_affiliation": "RenJi Hospital", 
            "investigator_full_name": "Jing Ma", 
            "investigator_title": "Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "RenJi Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RenJi Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}